NIA-Funded Alzheimer Centers Are More Efficient than Commercial Clinical Recruitment Sites for Conducting Secondary Prevention Trials of Dementia

Department of Neurosciences, University of California San Diego, La Jolla, CA, USA.
Alzheimer disease and associated disorders (Impact Factor: 2.44). 04/2010; 24(2):159-64. DOI: 10.1097/WAD.0b013e3181c9983f
Source: PubMed


Study participant dropout compromises clinical trials by reducing statistical power and potentially biasing findings. We use data from a trial of treatments to delay the progression of mild cognitive impairment to Alzheimer disease (AD) [NEJM 2005;352 (23):79 to 88] to determine predictors of study participant dropout and inform the design and implementation of future trials. Time to study discontinuation was modeled by proportional hazards regression with censoring at incident dementia or trial completion. Of 769 participants, 230 (30%) discontinued prematurely. Risk of dropout was higher among nonwhites [hazard ratio (HR) 2.1, P=0.0007], participants with less than college education (HR=1.6, P=0.02), participants with a Hamilton Depression score of 6 or more (HR=1.3, P=0.04), unmarried males (HR=2.1 relative to married males, P=0.003) and participants recruited by commercial clinical sites (HR=2.2 relative to participants recruited by NIA-funded AD research centers, P<0.0001). A trial using commercial sites with the discontinuation rates and incident dementia event rates experienced in this trial would require 80% more participants than a comparably powered trial using NIA-funded AD research center sites. Targeted retention efforts and utilization of academic sites could substantively improve the statistical power and validity of future clinical trials of cognitively impaired elderly.

7 Reads
  • Source
    • "Furthermore, the analysis suggested that participants recruited to commercial trial sites (as opposed to academic sites) were at increased risk to drop out of a trial. Dropout rates at commercial sites were nearly double those of sites that were AD research centers funded by the National Institute on Aging [40]. In line with their analyses, in the trials that we reviewed, those with the largest study size (and as such were most likely to enlist non-academic sites) had the lowest retention rates. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Among the key challenges in Alzheimer's disease drug development is the timely completion of clinical trials. Unfortunately, clinical trials often suffer from slow or insufficient enrollment. Successful clinical trial recruitment describes a balance between expeditiously achieving full enrollment and ensuring an appropriate study sample. Investigators face a number of challenges to the successful negotiation of this balance. The failure to address these challenges means that drug development may take more time and money and that trial results may not adequately represent drug efficacy or may not be applicable beyond the study. We review the challenges to recruitment and retention in Alzheimer's disease clinical trials and present a framework to address them.
    Alzheimer's Research and Therapy 12/2010; 2(6):34. DOI:10.1186/alzrt58 · 3.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The number of clinical trials for Alzheimer's disease conducted outside the United States in a broad array of countries is increasing. As the number of compounds ready for clinical testing increases, and as trials become longer and more complex, this trend is expected to grow. The cultural and ethical context of global clinical trials, potential benefits for those involved, and practical approaches to obstacles generated by these global trials were discussed at a meeting of the Alzheimer's Association Research Roundtable. Regulatory issues, including regional differences in study registration procedures, rules for collecting and reporting serious adverse events, requirements for national identity of study populations, and regulatory audits were also discussed by individuals who are knowledgeable about global clinical trials for Alzheimer's disease.
    Alzheimer's & dementia: the journal of the Alzheimer's Association 03/2011; 7(2):197-207. DOI:10.1016/j.jalz.2011.01.001 · 12.41 Impact Factor
  • Source

    Journal de Réadaptation Médicale Pratique et Formation en Médecine Physique et de Réadaptation 06/2011; 54(2). DOI:10.1016/
Show more


7 Reads
Available from